このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

選択した固形腫瘍を有する参加者における他の抗がん療法の有無にかかわらず MK-7684A (MK-7684A-005) (KEYVIBE-005)

2026年9月3日 更新者:Merck Sharp & Dohme LLC

選択された固形腫瘍の参加者における他の抗がん療法の有無にかかわらず、ビボストリマブ(MK-7684)とペムブロリズマブ(MK-3475)の共形成であるMK-7684Aの多施設共同非盲検第2相バスケット研究

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. The primary hypothesis is that pembrolizumab/vibostolimab co-formulation is superior to pembrolizumab alone in terms of objective response rate or progression-free survival in participants with cervical cancer.

調査の概要

研究の種類

介入

入学 (実際)

611

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Alaska
      • Anchorage、Alaska、アメリカ、99508
        • Alaska Womens Cancer Care ( Site 1016)
    • California
      • Duarte、California、アメリカ、91010
        • City of Hope Comprehensive Cancer Center ( Site 1001)
      • Orange、California、アメリカ、92868-3201
        • University of California, Irvine (UCI) Health - UC Irvine Me-Chao Family Comprehensive Cancer Cente
    • Michigan
      • Detroit、Michigan、アメリカ、48201
        • Karmanos Cancer Institute ( Site 1007)
    • New Jersey
      • Basking Ridge、New Jersey、アメリカ、07920
        • Memorial Sloan Kettering - Basking Ridge ( Site 1023)
      • Middletown、New Jersey、アメリカ、07748
        • Memorial Sloan Kettering - Monmouth ( Site 1022)
      • Montvale、New Jersey、アメリカ、07645
        • Memorial Sloan Kettering - Bergen ( Site 1025)
    • New York
      • Commack、New York、アメリカ、11725
        • Memorial Sloan Kettering- Commack ( Site 1021)
      • Harrison、New York、アメリカ、10604
        • Memorial Sloan Kettering - Westchester ( Site 1020)
      • New York、New York、アメリカ、10065
        • Memorial Sloan Kettering Cancer Center ( Site 1002)
      • Uniondale、New York、アメリカ、11553
        • Memorial Sloan Kettering - Nassau ( Site 1026)
    • Oklahoma
      • Tulsa、Oklahoma、アメリカ、74146
        • Oklahoma Cancer Specialists and Research Institute, LLC ( Site 1024)
    • South Dakota
      • Sioux Falls、South Dakota、アメリカ、57104
        • Sanford Cancer Center-Gynecologic Oncology ( Site 1015)
    • Texas
      • Houston、Texas、アメリカ、77030
        • Houston Methodist Hospital ( Site 1017)
      • Haifa、イスラエル、3109601
        • Rambam Health Care Campus-Oncology ( Site 1141)
      • Jerusalem、イスラエル、9112001
        • Hadassah Medical Center-Oncology ( Site 1142)
      • Ramat Gan、イスラエル、5265601
        • Sheba Medical Center-ONCOLOGY ( Site 1144)
      • Tel Aviv、イスラエル、6423906
        • Sourasky Medical Center-Oncology ( Site 1143)
      • Milan、イタリア、20141
        • Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative (
      • Naples、イタリア、80131
        • Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Sperimentazioni Cliniche ( Site 1134)
    • Lazio
      • Rome、Lazio、イタリア、00168
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Ginecologia Oncologica ( Site 1136)
    • Lombardy
      • Milan、Lombardy、イタリア、20132
        • Ospedale San Raffaele-Oncologia Medica ( Site 1135)
    • Milano
      • Rozzano、Milano、イタリア、20089
        • Istituto Clinico Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1138)
    • North Holland
      • Amsterdam、North Holland、オランダ、1066CX
        • Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 1121)
    • South Holland
      • Rotterdam、South Holland、オランダ、3015 GD
        • Erasmus Medisch Centrum-Medical Oncology ( Site 1122)
    • Ontario
      • Kingston、Ontario、カナダ、K7L 2V7
        • Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 1051)
      • Toronto、Ontario、カナダ、M5G 2M9
        • Princess Margaret Cancer Centre ( Site 1056)
    • Antioquia
      • Medellín、Antioquia、コロンビア、050030
        • Fundacion Colombiana de Cancerología Clinica Vida ( Site 1422)
    • Atlántico
      • Barranquilla、Atlántico、コロンビア、080020
        • Clinica de la Costa S.A.S. ( Site 1421)
    • Cundinamarca
      • Bogotá、Cundinamarca、コロンビア、111511
        • Instituto Nacional de Cancerología-Clinical Oncology ( Site 1425)
    • Risaralda Department
      • Pereira、Risaralda Department、コロンビア、661001
        • Oncologos del Occidente ( Site 1424)
    • Santander Department
      • Piedecuesta、Santander Department、コロンビア、681017
        • Fundación Cardiovascular de Colombia ( Site 1423)
      • Madrid、スペイン、28027
        • Clinica Universidad de Navarra-Medical Oncology ( Site 1118)
      • Seville、スペイン、41013
        • HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO ( Site 1114)
    • Barcelona
      • Hospitalet、Barcelona、スペイン、08907
        • Instituto Catalan de Oncologia - Hospital Duran i Reynals-Medical Oncology ( Site 1113)
    • Madrid
      • Pozuelo de Alarcón、Madrid、スペイン、28223
        • HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 1117)
    • Madrid, Comunidad de
      • Madrid、Madrid, Comunidad de、スペイン、28034
        • Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1111)
    • Araucania
      • Temuco、Araucania、チリ、4800827
        • James Lind Centro de Investigacion del Cancer ( Site 1404)
    • Region M. de Santiago
      • Santiago、Region M. de Santiago、チリ、7500921
        • FALP-UIDO ( Site 1401)
      • Santiago、Region M. de Santiago、チリ、7510032
        • Oncovida ( Site 1405)
      • Santiago、Region M. de Santiago、チリ、8420383
        • Bradfordhill-Clinical Area ( Site 1402)
      • Adana、トルコ(Türkiye)、01250
        • Baskent University Dr. Turgut Noyan Research and Training Center ( Site 1201)
      • Ankara、トルコ(Türkiye)、06230
        • Hacettepe Universitesi-oncology hospital ( Site 1209)
      • Ankara、トルコ(Türkiye)、06800
        • Ankara City Hospital-Medical Oncology ( Site 1202)
      • Edirne、トルコ(Türkiye)、22030
        • Trakya University-Medical Oncology ( Site 1207)
      • Istanbul、トルコ(Türkiye)、34303
        • Acibadem Universitesi Atakent Hastanesi ( Site 1208)
      • Istanbul、トルコ(Türkiye)、34722
        • TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1204)
    • Istanbul
      • Istanbul- Fatih、Istanbul、トルコ(Türkiye)、34098
        • Istanbul Universitesi Cerrahpasa ( Site 1203)
      • Berlin、ドイツ、12203
        • Charite Universitätsmedizin Berlin Campus Benjamin Franklin ( Site 1171)
    • Baden-Wurttemberg
      • Heidelberg、Baden-Wurttemberg、ドイツ、69120
        • Universitaetsklinikum Heidelberg-Nationales Centrum für Tumorerkrankungen ( Site 1180)
      • Tübingen、Baden-Wurttemberg、ドイツ、72076
        • Universitaetsklinikum Tuebingen-Department of Internal Medicine VIII - Medical Oncology, ECTU, Pne
    • Bavaria
      • München、Bavaria、ドイツ、81337
        • Klinikum der Universität München Großhadern ( Site 1176)
    • North Rhine-Westphalia
      • Düsseldorf、North Rhine-Westphalia、ドイツ、40225
        • Universitaetsklinikum Duesseldorf-Gastroenterology, Hepatology and Infectiology ( Site 1172)
      • Paris、フランス、75248
        • Institut Curie ( Site 1152)
    • Auvergne-Rhône-Alpes
      • Lyon、Auvergne-Rhône-Alpes、フランス、69373 Cedex 08
        • CENTRE LEON BERARD-Medical oncology ( Site 1151)
    • Cote-d Or
      • Dijon、Cote-d Or、フランス、21079
        • Centre Georges François Leclerc ( Site 1155)
    • Herault
      • Montpellier、Herault、フランス、34298
        • Institut Regional du Cancer Montpellier ( Site 1157)
    • Paris
      • Villejuif、Paris、フランス、94800
        • Gustave Roussy-medicine departement ( Site 1153)
    • Vaucluse
      • Avignon、Vaucluse、フランス、84000
        • Sainte Catherine Institut du Cancer Avignon Provence-Oncologie médicale ( Site 1156)
    • Masovian Voivodeship
      • Warsaw、Masovian Voivodeship、ポーランド、02-781
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Oddzial Badan Wczesnych Faz ( Site 1101
    • Pomeranian Voivodeship
      • Gdansk、Pomeranian Voivodeship、ポーランド、80-952
        • Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 1103)
    • West Pomeranian Voivodeship
      • Koszalin、West Pomeranian Voivodeship、ポーランド、75-581
        • Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 1104)
      • Tainan、台湾、704
        • NATIONAL CHENG-KUNG UNI. HOSP.-clinical trial center ( Site 1302)
      • Taipei、台湾、10002
        • National Taiwan University Hospital-Oncology ( Site 1301)
      • Taipei、台湾、10449
        • Mackay Memorial Hospital ( Site 1305)
      • Taoyuan、台湾、333
        • Chang Gung Medical Foundation-Linkou Branch ( Site 1304)
      • Osaka、日本、541-8567
        • Osaka International Cancer Institute ( Site 1323)
      • Tokyo、日本、104-0045
        • National Cancer Center Hospital ( Site 1322)
    • Aichi-ken
      • Nagoya、Aichi-ken、日本、464-8681
        • Aichi Cancer Center Hospital ( Site 1324)
    • Chiba
      • Kashiwa、Chiba、日本、277-8577
        • National Cancer Center Hospital East ( Site 1321)
      • Seoul、韓国、03080
        • Seoul National University Hospital-Internal Medicine ( Site 1312)
      • Seoul、韓国、03722
        • Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1311)
      • Seoul、韓国、05505
        • Asan Medical Center ( Site 1313)

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • One of the following histologically or cytologically confirmed, advanced (unresectable or metastatic) solid tumors:

    • Squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix
    • Endometrial cancer
    • Head and neck squamous cell carcinoma (HNSCC)
    • Unresectable biliary adenocarcinoma (gallbladder or biliary tree [intrahepatic or extrahepatic] cholangiocarcinoma)
    • Adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the gastroesophageal junction (GEJ).
    • Triple-negative breast cancer (TNBC)
    • Hepatocellular carcinoma (HCC)
    • Urothelial carcinoma of the renal pelvis, ureter, bladder, or urethra
    • Ovarian cancer
    • Gastric cancer
  • Measurable disease per RECIST v1.1 as assessed by BICR or local site investigator.

  • Adequately controlled blood pressure (BP) with or without antihypertensive medications.

  • Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART).

  • Male participants must agree to follow contraceptive guidance.

  • Female participants are not pregnant or breastfeeding, not a woman of child-bearing potential (WOCBP) or is a WOCBP and agrees to follow contraceptive guidance.

  • Adequate organ function.

Exclusion Criteria:

  • History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.
  • Prior therapy with anti-programmed cell-death (PD-1), anti-PD-L1, anti-PD-L2, or anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT) agent.
  • Prior systemic anticancer therapy including investigational agents within 4 weeks before randomization/allocation.
  • Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.
  • Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days before the first dose of study medication.
  • Active autoimmune disease that has required systemic treatment in past 2 years.
  • Active infection requiring systemic therapy.
  • Concurrent active hepatitis B and hepatitis C virus infection.
  • History of allogenic tissue/solid organ transplant.
  • Previous treatment with lenvatinib (for participants who will receive lenvatinib in their assigned treatment arm).
  • Has clinically significant cardiovascular disease within 12 months from first dose of study intervention.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Pembrolizumab/Vibostolimab Co-Formulation

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion every 3 weeks (Q3W) up to 35 cycles. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy.

Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

他の名前:
  • MK-7684A

Pembrolizumab 200 mg administered via IV infusion Q3W.

他の名前:
  • MK-3475
  • キイトルーダ®
実験的:Pembrolizumab

Participants receive pembrolizumab 200 mg via IV infusion Q3W up to 35 cycles.

Pembrolizumab 200 mg administered via IV infusion Q3W.

他の名前:
  • MK-3475
  • キイトルーダ®
実験的:Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Endometrial Cancer Cohort)

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion Q3W up to 35 cycles, plus lenvatinib 20 mg once daily (qd) up to 45 cycles. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Lenvatinib.

Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

他の名前:
  • MK-7684A

Pembrolizumab 200 mg administered via IV infusion Q3W.

他の名前:
  • MK-3475
  • キイトルーダ®

Lenvatinib 20 mg, 12 mg, or 8 mg (dependent on cancer type and body weight) administered via oral capsule QD

他の名前:
  • E7080
  • レンビマ
  • MK-7902
実験的:Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Hepatocellular Cancer Cohort)

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion Q3W up to 35 cycles, plus lenvatinib 12 mg (body weight [BW] ≥60 kg) or lenvatinib 8 mg (BW <60 kg) qd up to 45 cycles. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Lenvatinib.

Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

他の名前:
  • MK-7684A

Pembrolizumab 200 mg administered via IV infusion Q3W.

他の名前:
  • MK-3475
  • キイトルーダ®

Lenvatinib 20 mg, 12 mg, or 8 mg (dependent on cancer type and body weight) administered via oral capsule QD

他の名前:
  • E7080
  • レンビマ
  • MK-7902
実験的:Pembrolizumab/Vibostolimab + 5-Fluorouracil + Cisplatin

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W, plus 5-fluorouracil (5-FU), plus Cisplatin as background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with 5-Fluorouracil + Cisplatin.

Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

他の名前:
  • MK-7684A

Pembrolizumab 200 mg administered via IV infusion Q3W.

他の名前:
  • MK-3475
  • キイトルーダ®

5-FU 800 mg/m^2/day administered via continuous IV infusion on each of days 1 to 5 Q3W for up to 35 cycles

他の名前:
  • 5-FU
  • フルラシル

Cisplatin administered via IV infusion

他の名前:
  • プラチノール
  • シスプラチナ
実験的:Pembrolizumab/Vibostolimab Co-Formulation + Paclitaxel

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus paclitaxel as background therapy until meeting discontinuation criteria. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Paclitaxel.

Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

他の名前:
  • MK-7684A

Pembrolizumab 200 mg administered via IV infusion Q3W.

他の名前:
  • MK-3475
  • キイトルーダ®

Paclitaxel administered via IV infusion at investigator's choice of dose

他の名前:
  • タキソール
  • アブラキサン
  • アンザタックス
実験的:Pembrolizumab/Vibostolimab Co-Formulation + Gemcitabine/Cisplatin

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus gemcitabine (until disease progression or unacceptable toxicity) and cisplatin (up to 8 cycles) as background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Gemcitabine/Cisplatin

Pembrolizumab 200 mg administered via IV infusion Q3W.

他の名前:
  • MK-3475
  • キイトルーダ®

Cisplatin administered via IV infusion

他の名前:
  • プラチノール
  • シスプラチナ

Gemcitabine administered via IV infusion on Day 1 and Day 8 of each 3-week cycle, until PD or unacceptable toxicity

実験的:Pembrolizumab/Vibostolimab Co-Formulation+ Carboplatin/Paclitaxel/Bevacizumab

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus carboplatin, paclitaxel, and bevacizumab as local standard of care (SOC) background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Carboplatin/Paclitaxel/Bevacizumab.

Pembrolizumab 200 mg administered via IV infusion Q3W.

他の名前:
  • MK-3475
  • キイトルーダ®

Paclitaxel administered via IV infusion at investigator's choice of dose

他の名前:
  • タキソール
  • アブラキサン
  • アンザタックス

Carboplatin administered via IV infusion at investigator's choice of dose and frequency

For participants who cannot receive paclitaxel due to hypersensitivity or adverse event (AE), docetaxel administered via IV infusion Q3W, Day 1 of each cycle for up to 5 cycles

Bevacizumab (or biosimilars such as MVASI®, Zirabev®, Aybintio®, ALYMSYS®, Abevmy®, Onbevezy®, Vegzelma®) administered via IV infusion Q3W; Day 1 of each 3-week cycle for up to 15 cycles

実験的:Pembrolizumab/Vibostolimab Co-Formulation + Capecitabine/Oxaliplatin

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus capecitabine and oxaliplatin as background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Capecitabine/Oxaliplatin.

Pembrolizumab 200 mg administered via IV infusion Q3W.

他の名前:
  • MK-3475
  • キイトルーダ®

Capecitabine administered via oral tablet twice daily on Days 1 to 14 of each cycle (Q3W) for up to 35 cycles

Oxaliplatin administered via IV infusion Q3W up to 35 cycles

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR) in Cohort A1
時間枠:Up to approximately 24 months

ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by blinded independent central review based on RECIST 1.1 was presented. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). The ORR was calculated using the Miettinen & Nurminen method stratified by prior bevacizumab use interactive voice response system (IVRS). ORR as assessed by BICR in Cohort A1 is presented.

Up to approximately 24 months
Progression-Free Survival (PFS) Per RECIST 1.1 as Assessed by BICR in Cohort A1
時間枠:Up to approximately 24 months

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS as assessed by BICR in Cohort A1 is presented.

Up to approximately 24 months
ORR Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors
時間枠:Up to approximately 24 months

ORR is defined as the percentage of participants who have a CR (Disappearance of all target lesions) or a PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR in selected solid tumors as assessed by investigator based on RECIST 1.1 is presented. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). Per protocol, Cohort A1 and Cohort I were excluded in the analysis. ORR as assessed by Investigator based on RECIST 1.1 is presented.

Up to approximately 24 months
Progression Free Survival (PFS) Per RECIST 1.1 as Assessed by Investigator at 9 Months
時間枠:9 months

PFS is defined as the time from the first dose of study intervention to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS-9 is defined as the proportion of participants free of documented progression per RECIST 1.1 by investigator or death due to any cause at 9 months from the first dose of study intervention. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS at 9 months as assessed by Investigator based on RECIST 1.1 in Cohort I is presented.

9 months
PFS Per RECIST 1.1 as Assessed by Investigator at 12 Months
時間枠:12 months

PFS is defined as the time from the first dose of study intervention to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS-12 is defined as the proportion of participants free of documented progression per RECIST 1.1 by investigator or death due to any cause at 12 months from the first dose of study intervention. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS at 12 months as assessed by Investigator based on RECIST 1.1 in Cohort I is presented.

12 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Overall Survival (OS) in Participants With Selected Solid Tumors
時間枠:Up to approximately 46 months

For Cohort A1 OS is defined as the time from randomization to death due to any cause. For Cohort A2 to Cohort J OS is defined as the time from the first dose of study intervention to death due to any cause. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data. OS in selected solid tumors is presented.

Up to approximately 46 months
PFS Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors
時間枠:Up to approximately 46 months

PFS is defined as the time from first dose of study treatment to the first documented PD or death due to any cause, whichever occurs first per RECIST 1.1 by Investigator for Cohort A2 to J. PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed Investigator in Cohort A2 to J is presented.

Up to approximately 46 months
Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR in Cohort A1
時間枠:Up to approximately 46 months

For participants who demonstrate a confirmed Complete Response (CR: Disappearance of all target lesions) or confirmed Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by BICR was presented for participants in Cohort A1.

Up to approximately 46 months
DOR Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors
時間枠:Up to approximately 46 months

For participants who demonstrate a confirmed Complete Response (CR: Disappearance of all target lesions) or confirmed Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by Investigator was presented.

Up to approximately 46 months
ORR Per RECIST 1.1 as Assessed by Investigator in Cohort A1
時間枠:Up to approximately 24 months

ORR is defined as the percentage of participants who have a CR (Disappearance of all target lesions) or a PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by investigator based on RECIST 1.1 in Cohort A1 is presented.

Up to approximately 24 months
PFS Per RECIST 1.1 as Assessed by Investigator in Participants in Cohort A1
時間枠:Up to approximately 24 months

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PDPer protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS as assessed by Investigator based on RECIST 1.1 in Cohort A1 is presented.

Up to approximately 24 months
Change From Baseline in Global Health Status/Quality of Life Score (European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 [EORTC QLQ-C30] Items 29 and 30) in Cohort A1
時間枠:Baseline and up to Week 12

The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score in Cohort A1 is presented.

Baseline and up to Week 12
Change From Baseline in Physical Functioning Score (EORTC QLQ-C30 Items 1-5) in Cohort A1
時間枠:Baseline and up to Week 12

The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better quality of life. The change from baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) score in Cohort A1 is presented.

Baseline and up to Week 12
Number of Participants Who Experienced One or More Adverse Events (AEs)
時間枠:Up to approximately 46 months

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants that experienced at least one AE was reported for each treatment arm.

Up to approximately 46 months
Number of Participants Who Discontinued Study Intervention Due to an AE
時間枠:Up to approximately 46 months

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants that discontinued any study drug due to an AE was reported for each treatment arm.

Up to approximately 46 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Medical Director、Merck Sharp & Dohme LLC

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年9月16日

一次修了 (実際)

2025年8月5日

研究の完了 (実際)

2025年8月5日

試験登録日

最初に提出

2021年8月10日

QC基準を満たした最初の提出物

2021年8月10日

最初の投稿 (実際)

2021年8月16日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月28日

QC基準を満たした最後の更新が送信されました

2026年9月3日

最終確認日

2026年8月1日

詳しくは

本研究に関する用語

追加の関連 MeSH 用語

その他の研究ID番号

  • 7684A-005
  • MK-7684A-005 (その他の識別子:MSD)
  • jRCT2031210335 (レジストリ識別子:jRCT)
  • KEYVIBE-005 (その他の識別子:MSD)
  • 2021-001009-56 (EudraCT番号)
  • U1111-1291-4290 (レジストリ識別子:UTN)
  • 2023-505284-36-00 (レジストリ識別子:EU CT)
  • 2023 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する